Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control

As the first step towards control of a strain specific epidemic of meningococcal disease in New Zealand (NZ), this study, an observer-blind, randomised controlled trial in 75 healthy adults, evaluated safety and immunogenicity of two different dosages of a meningococcal group B vaccine administered in a three dose regime. The “tailor-made” outer membrane vesicle (OMV) vaccine (candidate vaccine) developed using a New Zealand meningococcal group B strain (B:4:P1.7b,4) was well tolerated with no vaccine related serious adverse events. Similar local and systemic reactions were observed in those receiving the New Zealand candidate vaccine and the control parent Norwegian vaccine (MenBvac™). A four-fold rise in serum bactericidal antibodies (SBAb) against the vaccine strain 4–6 weeks after the third vaccination was achieved in 100% of New Zealand candidate vaccine 2519 μg participants and in 87% of 50 μg participants. The safety and immunogenicity profile observed in this study of healthy adults enabled studies in children to be initiated using 25 μg dosage.